Once-daily dolutegravir is non-inferior to twice-daily raltegravir in treatment-naïve adults with HIV-1
27 July 2012 | By GlaxoSmithKline
Findings support progression towards registration...
List view / Grid view
27 July 2012 | By GlaxoSmithKline
Findings support progression towards registration...
25 July 2012 | By GlaxoSmithKline
GSK delivers Q2 core EPS of 26.4p and dividend of 17p...
17 July 2012 | By GlaxoSmithKline
Fabry products to be commercialised by Amicus in US and by GSK ex-US...
16 July 2012 | By GlaxoSmithKline
GSK to acquire full ownership of BENLYSTA®, albiglutide and darapladib...
16 July 2012 | By GlaxoSmithKline
GSK launches new advertising campaign...
13 July 2012 | By GlaxoSmithKline
Relvar™ and Breo™ proposed as brand names for FF/VI in EU and US...
12 July 2012 | By GlaxoSmithKline
GlaxoSmithKline has withdrawn a supplemental New Drug Application to the US FDA for Tykerb...
11 July 2012 | By GlaxoSmithKline
Data has been received from the Phase III Harmony 8 study...
11 July 2012 | By GlaxoSmithKline
Phase III SINGLE study results...
6 July 2012 | By Abbott
Groundbreaking partnership that aims to speed the discovery of essential new treatments...
2 July 2012 | By GlaxoSmithKline
Agreement reached with the US Government...
2 July 2012 | By GlaxoSmithKline
Results from the pivotal efficacy studies...
29 June 2012 | By GlaxoSmithKline
Expiration is after HGS process bid deadline of 16 July...
15 June 2012 | By GlaxoSmithKline
GSK has received a renewed invitation from Human Genome Sciences’...
14 June 2012 | By GlaxoSmithKline
First combination vaccine to help prevent meningococcal serogroups C and Y and Hib disease...